|
Volumn 159, Issue 3, 2008, Pages 760-761
|
Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis
|
Author keywords
Efalizumab; Efficacy; Etanercept; Guideline; History; Psoriasis
|
Indexed keywords
CYCLOSPORIN A;
EFALIZUMAB;
ETANERCEPT;
METHOTREXATE;
ADULT;
AGED;
CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG TREATMENT FAILURE;
FEMALE;
FOLLOW UP;
HEALTH INSURANCE;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
NETHERLANDS;
PHOTOTHERAPY;
PRIORITY JOURNAL;
PSORIASIS;
REIMBURSEMENT;
TREATMENT CONTRAINDICATION;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIBODIES, MONOCLONAL;
DRUG COSTS;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
MIDDLE AGED;
NETHERLANDS;
PSORIASIS;
REIMBURSEMENT MECHANISMS;
|
EID: 49749132364
PISSN: 00070963
EISSN: 13652133
Source Type: Journal
DOI: 10.1111/j.1365-2133.2008.08729.x Document Type: Letter |
Times cited : (4)
|
References (6)
|